ClinicalTrials.gg
Not yet recruitingNCT06797700RFPMDLSUpdated Mar 5, 2025

Risk Factors of Paraspinal Muscles in Degenerative Lumbar Spondylolisthesis

An observational study in Spine Degeneration, sponsored by The First People's Hospital of Yunnan. Not yet recruiting at 1 site in China. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-03-05.

Sponsored by The First People's Hospital of Yunnan · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 6 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
1,000
Ages
50 Years to 80 Years
Sex
All
01

Study summary

This is a retrospectively observational study. The goal of this observational study is to analyze the risk factors of paraspinal muscles associated with the occurrence of spondylolisthesis in patients with degenerative lumbar spondylolisthesis(DLS) and to construct a predictive model. The main question it aims to answer is: Which paraspinal muscle changes are risk factors for DLS? We will collect the information of patients who have undergone lumbar MRI in our hospital and have been diagnosed with back pain ( including spondylolisthesis or no spondylolisthesis) during the period from 2022 to 2024.The collected data included gender, age, body mass index (BMI), diabetes, hypertension, occupation and imaging parameters. We will then retrospectively analyze the risk factors associated with lumbar spondylolisthesis.

02

Conditions studied

  • Spine Degeneration

Keywords

  • degenerative lumbar spondylolisthesis
  • paraspinal muscles
  • MRI
03

In context

Lead sponsor

The First People's Hospital of Yunnan is the lead sponsor of 6 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who have undergone lumbar MRI in our hospital and have been diagnosed with back pain ( including spondylolisthesis or no spondylolisthesis) during the period from 2022 to 2024.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who presented to our hospital with back pain(the diagnosis was spondylolisthesis or no spondylolisthesis);
  • Patients older than 50 years;
  • Patients with complete clinical data and magnetic resonance imaging (MRI) before surgery.

Exclusion criteria

Exclusion Criteria:

  • The patient has previous spinal surgery;
  • Patients with lumbar tumor,lumbar infection and lumbar tuberculosis;
  • Patients with incomplete MRI sequence.
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group A

    patients without lumbar spondylolisthesis

  • Group B

    patients with lumbar spondylolisthesis

06

What researchers measure

Primary outcomes

  1. the MF FCSA

    The functional cross-sectional areas of the multifidus muscl.Measurement it on axial T2-weighted magnetic resonance (MR) images from the L4 vertebral body levels

    Time frame: Two weeks before treatment

  2. the ES FCSA

    The functional cross-sectional areas of the erector spinae.Measurement it on axial T2-weighted magnetic resonance (MR) images from the L4 vertebral body levels

    Time frame: Two weeks before treatment

  3. the MF CSA

    the total cross-sectional areas of the multifidus muscl.Measurement it on axial T2-weighted magnetic resonance (MR) images from the L4 vertebral body levels

    Time frame: Two weeks before treatment

  4. the ES CSA

    the total cross-sectional areas of the erector spinae.Measurement it on axial T2-weighted magnetic resonance (MR) images from the L4 vertebral body levels

    Time frame: Two weeks before treatment

Secondary outcomes

  1. SMI

    The skeletal muscle index.SMI = l CSA of muscle on an axial scan (expressed as cm2) divided by the square of the patient's height (expressed as cm2).

    Time frame: Two weeks before treatment

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2025; primary completion for Apr 2025, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2025
First posted
Jan 28, 2025
StartEst.
Mar 6, 2025
Primary completionEst.
Apr 30, 2025
CompletionEst.
Aug 31, 2025
Last update
Mar 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06797700
Lead sponsor
The First People's Hospital of Yunnan
Responsible party
Xinyun li (miss, The First People's Hospital of Yunnan) — Principal investigator
First posted
Jan 28, 2025
Start date
Mar 6, 2025 (estimated)
Primary completion
Apr 30, 2025 (estimated)
Completion
Aug 31, 2025 (estimated)
Last update
Mar 5, 2025

Study contacts

Xinyun Li
Contact
15750359757@163.com
86+15750359757

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion